785 results on '"Zheng, X. Long"'
Search Results
2. A mutant complement factor H (W1183R) enhances proteolytic cleavage of von Willebrand factor by ADAMTS-13 under shear
3. Genetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura
4. Thymidine phosphorylase mediates SARS-CoV-2 spike protein enhanced thrombosis in K18-hACE2TG mice
5. Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura
6. Targeting neutrophil extracellular trap accumulation under flow in patients with immune-mediated thrombotic thrombocytopenic purpura
7. A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura
8. Coagulation factor VIII regulates von Willebrand factor homeostasis invivo
9. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice
10. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura
11. A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen−deuterium exchange plus mass spectrometry
12. Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19
13. Abstract 17158: Effects of Human Monoclonal Antibodies on ADAMTS13 in Immune Thrombotic Thrombocytopenic Purpura
14. Protein arginine methyltransferase 1 in the generation of immune megakaryocytes: A perspective review
15. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura
16. ADAMTS13 protease or lack of von Willebrand factor protects irradiation and melanoma‐induced thrombotic microangiopathy in zebrafish
17. Race, rituximab, and relapse in TTP
18. Low ADAMTS‐13 predicts adverse outcomes in hospitalized patients with suspected heparin‐induced thrombocytopenia
19. The standard of care for immune thrombotic thrombocytopenic purpura today
20. A human monoclonal antibody against the distal carboxyl terminus of ADAMTS‐13 modulates its susceptibility to an inhibitor in thrombotic thrombocytopenic purpura
21. Plasma levels of S100A8/A9, histone/DNA complexes, and cell‐free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura
22. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura
23. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura
24. Identification of cysteine thiol‐based linkages in ADAMTS13 in support of a non‐proteolytic regulation of von Willebrand factor
25. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy
26. Human neutrophil peptide‐1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols
27. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
28. Thymidine Phosphorylase Mediates SARS-CoV-2 Spike Protein Enhanced Thrombosis in K18-hACE2TGMice
29. Mechanism underlying severe deficiency of plasma ADAMTS13 activity in immune thrombotic thrombocytopenic purpura
30. A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry
31. Clinical Utility of Recently Food and Drug Administration-Approved IntelliSep Test (Sepsis Biomarker) for Early Diagnosis of Sepsis: Comparison with Other Biomarkers.
32. ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.
33. Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura.
34. Thrombotic thrombocytopenic purpura: 100 years of research on Moschcowitz syndrome
35. Binding of Platelet Glycoprotein Ibα to Von Willebrand Factor Domain A1 Stimulates the Cleavage of the Adjacent Domain A2 by ADAMTS13
36. Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection
37. Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review
38. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura
39. Dynamic Measurement of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV2 Infection
40. HTRS2023.P4.13 Antibody mediated pathophysiology of immune thrombotic thrombocytopenic purpura
41. How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
42. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura
43. ADAMTS13: Structure and Function
44. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia
45. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis in Mice and in Human
46. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models
47. Understanding thrombotic microangiopathies in children
48. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation
49. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome
50. Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.